Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.

Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA.

Breast Cancer Res Treat. 2012 Oct;135(3):875-83. doi: 10.1007/s10549-012-2209-z. Epub 2012 Aug 26.

2.

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS.

Oncologist. 2013;18(5):501-10. doi: 10.1634/theoncologist.2012-0414. Epub 2013 May 7.

3.

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.

Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA.

Breast Cancer Res Treat. 2013 Oct;141(3):461-70. doi: 10.1007/s10549-013-2697-5. Epub 2013 Sep 24.

4.

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU.

Breast. 2013 Aug;22(4):525-31. doi: 10.1016/j.breast.2012.12.006. Epub 2013 Jan 23.

5.

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.

Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D.

Breast Cancer Res Treat. 2014 Jun;145(3):725-34. doi: 10.1007/s10549-014-2916-8. Epub 2014 Apr 6.

6.

Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.

Gümüş M, Davidson N, Bauknecht T, Soldatenkova V, Benhadji KA.

Curr Med Res Opin. 2012 Mar;28(3):401-13. doi: 10.1185/03007995.2011.651795. Epub 2012 Jan 31.

PMID:
22181343
7.

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.

Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15.

PMID:
23673443
8.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.

9.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
10.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.

11.

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.

Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15.

PMID:
24036907
12.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.

Clin Oncol (R Coll Radiol). 2014 Feb;26(2):81-9. doi: 10.1016/j.clon.2013.08.011. Epub 2013 Sep 17.

PMID:
24051172
13.

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA.

Clin Cancer Res. 2011 Jul 15;17(14):4834-43. doi: 10.1158/1078-0432.CCR-10-2962.

14.

Trastuzumab in advanced breast cancer--a decade of experience in Germany.

Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich HD, Tesch H, Wohlfarth T, Eustermann H, Hinke A.

BMC Cancer. 2014 Dec 8;14:924. doi: 10.1186/1471-2407-14-924.

15.

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A.

J Clin Oncol. 2009 Nov 20;27(33):5529-37. doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28.

16.

Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F.

Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.

PMID:
24210572
17.

Trastuzumab containing regimens for early breast cancer.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006243. doi: 10.1002/14651858.CD006243.pub2. Review.

PMID:
22513938
18.

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R.

Breast J. 2013 Mar-Apr;19(2):149-55. doi: 10.1111/tbj.12070. Epub 2013 Jan 27.

PMID:
23350584
19.

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M.

Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.

20.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk